幽门螺杆菌感染与免疫性血小板减少症的相关性分析

Correlation between Helicobacter pylori infection and immune thrombocytopenia

  • 摘要: 目的 探讨幽门螺杆菌感染与免疫性血小板减少症的相关性。 方法 选取本院收治的112例初诊免疫性血小板减少症患者为观察组,同期抽取112例健康体检者为对照组。根据治疗结果差异,观察组幽门螺杆菌感染患者(n=42)平均分为根治组与未根治组,比较根治组、未根治组治疗效果及复发情况。对比观察组和对照组幽门螺杆菌感染情况。 结果 观察组幽门螺杆菌感染阳性率显著高于对照组(37.50% vs. 21.43%,P<0.05); 根治组治疗效果略高于未根治组,但差异无统计学意义(80.95% vs. 76.19%, P>0.05); 根治组复发率显著低于未根治组(14.29% vs. 38.10%, P<0.05)。 结论 幽门螺杆菌感染与免疫性血小板减少症存在一定相关性。非初诊免疫性血小板减少症患者中,幽门螺杆菌感染并非主要致病因素,幽门螺杆菌根治对早期疗效影响不大,但可减少免疫性血小板减少症的复发。

     

    Abstract: Objective To investigate the correlation between Helicobacter pylori infection and immune thrombocytopenia. Methods A total of 112 patients with newly diagnosed as immune thrombocytopenia admitted to our hospital were enrolled in observation group. Another 112 healthy subjects were selected as control group during the same period. According to the results of treatment, the Helicobacter pylori-positive patients(n=42)in the observation group were further divided into radical treatment group and non-radical treatment group. Treatment effects and recurrence of radical treatment group and non-radical treatment group were statistically compared. And the conditions of Helicobacter pylori infection in control group and observation group were analyzed. Results The positive rate of Helicobacter pylori infection in the observation was significantly higher than that in the control group(37.50% vs. 21.43%, P<0.05). In terms of treatment effect, the radical treatment group was slightly higher than the non-radical treatment group, but the difference was not statistically significant(80.95% vs. 76.19%, P>0.05); the radical group was significantly lower in recurrence rate than the non-radical treatment group(14.29% vs. 38.10%, P<0.05). Conclusion There is a certain correlation between Helicobacter pylori infection and immune thrombocytopenia. However, in the newly diagnosed patients with immune thrombocytopenia, Helicobacter pylori infection is not the main pathogenic factor, so Helicobacter pylori radical treatment has little effect on early efficacy, but can reduce the recurrence of immune thrombocytopenia.

     

/

返回文章
返回